Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Amycretin cycle length: what human studies ran

InvestigationalAHuman trial evidence
Short answer: there is no established Amycretin cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. Phase 2 subcutaneous and oral trials in type 2 diabetes: 3-week screening, 36-week intervention and 4-week follow-up 3,4.
  2. Subcutaneous phase 1b/2a: 36 weeks (Part B, to 60 mg; Part C, to 20 mg), 28 weeks (Part D, 5 mg) and 20 weeks (Part E, 1.25 mg) 2. Oral first-in-human: single dose with 21-day follow-up (Part A), 10 days of dosing (Part B), 12 weeks of dosing with 3-week follow-up (Part C/D) 1.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Amycretin combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Amycretin cycle length?
No. Human studies administered Amycretin for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of Amycretin?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Amycretin dosing reference Full research page

References

  1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial Lancet. 2025
  2. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study Lancet. 2025
  3. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial Lancet. 2026
  4. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial Lancet. 2026
  5. The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats EBioMedicine. 2025
  6. AMAZE 7: zenagamtide compared with semaglutide in people with excess body weight (NCT07668414) ClinicalTrials.gov. 2026
  7. AMBIENCE: zenagamtide compared with placebo in people with established atherosclerotic cardiovascular disease and overweight or obesity (NCT07861100) ClinicalTrials.gov. 2026
  8. Drugs@FDA application data queried through openFDA for amycretin and zenagamtide (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
  9. PubChem substance record for amycretin (SID 530736542) PubChem. 2026
  10. World Anti-Doping Agency International Standard Prohibited List 2026 WADA. 2026
  11. Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide Diabetes Obes Metab. 2026
  12. AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight (NCT07720271) ClinicalTrials.gov. 2026
  13. AMBITION 7: zenagamtide compared to insulin glargine in people with type 2 diabetes and increased cardiovascular risk (NCT07797335) ClinicalTrials.gov. 2026
  14. Zenagamtide (amycretin) phase 2 dose-finding trial in type 2 diabetes, registry record (NCT06542874) ClinicalTrials.gov. 2024